search
Back to results

Supplemental Selenium and Vitamin E and Pulmonary Function

Primary Purpose

Chronic Obstructive Pulmonary Disease, Lung Diseases, Lung Diseases, Obstructive

Status
Completed
Phase
Phase 3
Locations
Study Type
Interventional
Intervention
Vitamin E
Selenium
Vitamin E placebo
Selenium placebo
Sponsored by
Cornell University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Chronic Obstructive Pulmonary Disease

Eligibility Criteria

50 Years - undefined (Adult, Older Adult)MaleAccepts Healthy Volunteers

Eligibility criteria: age ≥ 55 y (≥ 50 y in African-Americans) serum prostate-specific antigen ≤ 4ng/mL no clinical evidence of prostate cancer Exclusion criteria: Off both SELECT supplements

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm 3

    Arm 4

    Arm Type

    Experimental

    Experimental

    Experimental

    Placebo Comparator

    Arm Label

    Vitamin E and selenium placebo

    Selenium and vitamin E placebo

    Vitamin E and selenium

    vitamin E Placebo and Selenium placebo

    Arm Description

    Vitamin E alone

    Selenium alone

    Vitamin E and selenium combined

    Double placebo

    Outcomes

    Primary Outcome Measures

    Change in pulmonary function over time by arm of study

    Secondary Outcome Measures

    Full Information

    First Posted
    June 26, 2003
    Last Updated
    December 8, 2017
    Sponsor
    Cornell University
    Collaborators
    National Heart, Lung, and Blood Institute (NHLBI)
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT00063453
    Brief Title
    Supplemental Selenium and Vitamin E and Pulmonary Function
    Official Title
    The Respiratory Ancillary Study (RAS) to SELECT
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    December 2017
    Overall Recruitment Status
    Completed
    Study Start Date
    August 2003 (undefined)
    Primary Completion Date
    August 2010 (Actual)
    Study Completion Date
    August 2010 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Cornell University
    Collaborators
    National Heart, Lung, and Blood Institute (NHLBI)

    4. Oversight

    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    To test whether supplementation with selenium and/or vitamin E affects pulmonary function.
    Detailed Description
    BACKGROUND: There is compelling evidence from observational epidemiologic studies that intakes of nutrients with antioxidant properties are associated with reduced risks of chronic obstructive disease (COPD) and increased lung function. This study is ancillary to the multisite Selenium and Vitamin E Cancer Prevention Trial (SELECT), a 4-arm placebo-controlled, double-blinded randomized trial in 35,000 men testing whether daily supplementation with vitamin E (400mg alpha-tocopherol), selenium (200 micrograms selenomethionine) or both vitamin E and selenium can prevent prostate cancer. DESIGN NARRATIVE: This study is ancillary to the multisite Selenium and Vitamin E Cancer Prevention Trial (SELECT), a 4-arm placebo-controlled, double-blinded randomized trial in 35,000 men testing whether daily supplementation with vitamin E (400mg alpha-tocopherol), selenium (200 micrograms selenomethionine) or both vitamin E and selenium can prevent prostate cancer. A total of 3,000 SELECT participants will be enrolled for this respiratory ancillary study, and data collection will be extended to include pulmonary function, respiratory disease, and respiratory symptoms. Biological measures of nutrient exposure (serum vitamin E and selenium) and plasma lipids (total and high-density lipoprotein cholesterol) will be collected on all participants and oxidant burden (urinary F2-isoprostane) on a sub sample of heavy smokers and men with COPD. The primary outcome will be change over about 36 months in forced expiratory volume in the first second (FEV1). FEV1 is a valid and reliable measure of respiratory function that strongly predicts COPD and mortality. Extensive data on diet and dietary supplement use are being collected by the SELECT parent study. All specific aims examine pre-specified contrasts between the 4 arms of the SELECT randomized trial. The underlying hypothesis is that supplements will reduce the age related decline in FEV1 and thus at the 3-year follow-up FEV1, which will be tested in longitudinal and cross-sectional models. A secondary aim considers whether the effect of supplementation is greater among smokers (high burden of exogenous oxidants) who, by purposive selection of the study sites, will comprise about 25% of the sample.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Chronic Obstructive Pulmonary Disease, Lung Diseases, Lung Diseases, Obstructive

    7. Study Design

    Primary Purpose
    Prevention
    Study Phase
    Phase 3
    Interventional Study Model
    Factorial Assignment
    Masking
    ParticipantInvestigatorOutcomes Assessor
    Allocation
    Randomized
    Enrollment
    2920 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Vitamin E and selenium placebo
    Arm Type
    Experimental
    Arm Description
    Vitamin E alone
    Arm Title
    Selenium and vitamin E placebo
    Arm Type
    Experimental
    Arm Description
    Selenium alone
    Arm Title
    Vitamin E and selenium
    Arm Type
    Experimental
    Arm Description
    Vitamin E and selenium combined
    Arm Title
    vitamin E Placebo and Selenium placebo
    Arm Type
    Placebo Comparator
    Arm Description
    Double placebo
    Intervention Type
    Dietary Supplement
    Intervention Name(s)
    Vitamin E
    Other Intervention Name(s)
    all rac-α-tocopheryl acetate
    Intervention Description
    vitamin E (400 IU/day all rac-α-tocopheryl acetate)
    Intervention Type
    Dietary Supplement
    Intervention Name(s)
    Selenium
    Other Intervention Name(s)
    L-selenomethionine
    Intervention Description
    selenium (200 μg/d L-selenomethionine)
    Intervention Type
    Dietary Supplement
    Intervention Name(s)
    Vitamin E placebo
    Other Intervention Name(s)
    Placebo
    Intervention Description
    placebo
    Intervention Type
    Dietary Supplement
    Intervention Name(s)
    Selenium placebo
    Other Intervention Name(s)
    placebo
    Intervention Description
    placebo
    Primary Outcome Measure Information:
    Title
    Change in pulmonary function over time by arm of study
    Time Frame
    Outcome is assessed at annual and bi-annual study visits, during in-person visit of participant to the study site. Over a period of about 36 to 48 months, participants are assessed between 3 and 4 times
    Other Pre-specified Outcome Measures:
    Title
    Effect of selenium and vitamin E supplementation on incidence of COPD
    Description
    The incidence of COPD will be assessed in the full SELECT trial, given this ancillary study added questionnaire data to assess self-reported incidence of lung disease in the full 35,000 participants
    Time Frame
    Questionnaire data on incident lung disease is assessed at annual and biannual study visits, in all SELECT participants. These questionnaire data were collected through the end of SELECT active follow-up, which was December 2010

    10. Eligibility

    Sex
    Male
    Minimum Age & Unit of Time
    50 Years
    Accepts Healthy Volunteers
    Accepts Healthy Volunteers
    Eligibility Criteria
    Eligibility criteria: age ≥ 55 y (≥ 50 y in African-Americans) serum prostate-specific antigen ≤ 4ng/mL no clinical evidence of prostate cancer Exclusion criteria: Off both SELECT supplements
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Patricia A. Cassano, PhD
    Organizational Affiliation
    Cornell University
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Citations:
    PubMed Identifier
    27519183
    Citation
    Goodman PJ, Tangen CM, Darke AK, Arnold KB, Hartline J, Yee M, Anderson K, Caban-Holt A, Christen WG, Cassano PA, Lance P, Klein EA, Crowley JJ, Minasian LM, Meyskens FL. Opportunities and challenges in incorporating ancillary studies into a cancer prevention randomized clinical trial. Trials. 2016 Aug 12;17:400. doi: 10.1186/s13063-016-1524-9.
    Results Reference
    derived
    PubMed Identifier
    27012420
    Citation
    Guertin KA, Grant RK, Arnold KB, Burwell L, Hartline J, Goodman PJ, Minasian LM, Lippman SM, Klein E, Cassano PA. Effect of long-term vitamin E and selenium supplementation on urine F2-isoprostanes, a biomarker of oxidative stress. Free Radic Biol Med. 2016 Jun;95:349-56. doi: 10.1016/j.freeradbiomed.2016.03.010. Epub 2016 Mar 22.
    Results Reference
    derived
    PubMed Identifier
    25889509
    Citation
    Cassano PA, Guertin KA, Kristal AR, Ritchie KE, Bertoia ML, Arnold KB, Crowley JJ, Hartline J, Goodman PJ, Tangen CM, Minasian LM, Lippman SM, Klein E. A randomized controlled trial of vitamin E and selenium on rate of decline in lung function. Respir Res. 2015 Mar 11;16(1):35. doi: 10.1186/s12931-015-0195-5.
    Results Reference
    derived

    Learn more about this trial

    Supplemental Selenium and Vitamin E and Pulmonary Function

    We'll reach out to this number within 24 hrs